Success story from 2023: Adragos Pharma takes over Sanofi’s production site in Japan

Early this year, our company achieved a significant milestone by acquiring a manufacturing site in Japan from Sanofi. This strategic move has expanded our global presence and solidified our position as one of the top three Contract Manufacturing Organizations (CMOs) in Japan.

The Sanofi production site in Kawagoe is one of Japan’s largest and technically advanced facilities. Adragos Pharma has access to this production site and its manufacturing capabilities. Under Sanofi, oral solids and ampoules were manufactured here. Additionally, it provided packaging, visual inspection, and QC test services for the Japanese and Asian markets.

This acquisition has allowed us to forge strong relationships with local suppliers and customers, further enhancing our presence in the market. Our team is dedicated to providing the highest quality services and products, and this expansion will allow us to serve our clients’ needs in Japan better.

We are committed to continuously improving operations and expanding our capabilities to provide the best possible services to our clients. 

The new milestone marks a significant step forward for Adragos Pharma, and the company is dedicated to upholding its values and principles in its new journey with its Japanese partners.

Being a young company, not as established in the market, we are entering a relationship with such a big company. This is quite a success, and I’m very proud of it.

Thank you for your continuous support and trust in our company. We look forward to building more partnerships and making significant strides in the global market. 

 

Marco Gorgas, Adragos CTO